Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | KIF11 | P52732 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29736372 | 0.99 | ALDH1A1 (0.36) | ALDH1A1PTGS2SLC6A3IDO1MEN1 | |
| SCHEMBL21955158 | 0.83 | USP2 (0.41) | ALDH1A1MEN1KMT2APOLB | |
| Hydrochloric Acid SCHEMBL21955355 | 0.82 | PKM (0.40) | ALDH1A1MEN1KMT2APOLB | |
| Hydrochloric Acid SCHEMBL21955352 | 0.82 | PKM (0.40) | ALDH1A1MEN1KMT2APOLB | |
| SCHEMBL25311998 | 0.78 | ALDH1A1 (0.36) | ALDH1A1PTGS2MEN1KMT2APOLB | |
| SCHEMBL25311996 | 0.78 | ALDH1A1 (0.36) | ALDH1A1PTGS2MEN1KMT2APOLB | |
| SCHEMBL22017697 | 0.78 | PTGS2 (0.33) | ALDH1A1PTGS2 | |
| SCHEMBL29736506 | 0.78 | PTGS2 (0.33) | ALDH1A1PTGS2 | |
| SCHEMBL29736356 | 0.78 | EZH2 (0.35) | ALDH1A1MEN1KMT2A | |
| SCHEMBL29736282 | 0.77 | MEN1 (0.36) | ALDH1A1PTGS2IDO1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11224600-B2 | Compounds for inhibition of alpha 4 beta 7 integrin | GILEAD SCIENCES, INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-20200155563-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200155563-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | ITGB7, ITGB4, ITGA4 | ALDH1A1 823/4885PTGS2 2563/4885SLC6A3 3820/4885 |
| US-11224600-B2 | Compounds for inhibition of alpha 4 beta 7 integrin | ITGB7, ITGB4, ITGA4 | ALDH1A1 823/4885PTGS2 2563/4885SLC6A3 3820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.